The Pancreatic-Cancer Pill That Doubles Survival: $39,800 a Month, and a Fast Lane Congress Never Approved

For the 252 patients in the RASolute 302 trial who drew standard chemotherapy, the math was the usual pancreatic-cancer math. Half of them were dead within six months and three weeks. That is not a failure of the trial; it is what metastatic pancreatic adenocarcinoma does, and has always done, to people who have already run through one round of treatment and watched the disease come back anyway.

The other 248 patients took a once-daily pill and lived, at the median, 13.2 months. Twice as long. That is the finding behind the FDA’s August 26 approval of Rasonque, generic name daraxonrasib, from the California biotech Revolution Medicines. The drug does what the release claims. What the release states more softly is the price, $477,600 a year, and the untested fast lane that carried it to market months early.

A gene everyone gave up on

Pancreatic cancer is where oncology drugs go to die. The RAS gene sits at the center of it, mutated in the overwhelming majority of these tumors and, for four decades, treated as essentially undruggable. Daraxonrasib is the first approved medicine to hit the broad RAS target rather than a single narrow mutant, and the trial built to prove it did not cut corners: 500 patients, randomized one to one, oral drug against the physician’s choice of chemotherapy, 248 on the pill and 252 on chemo.

The numbers held up across the board. Median overall survival of 13.2 months versus 6.7, a hazard ratio of 0.40 (95% CI, 0.30 to 0.53), which is the clinical way of saying the drug cut the risk of death by 60 percent, with a p-value under 0.0001. Progression-free survival roughly doubled too, 7.3 months against 3.5. Nearly a third of patients saw their tumors shrink, 33.2 percent against 11.8 percent on chemo. And it was easier to tolerate than the chemotherapy it replaced: serious treatment-related side effects hit 10.8 percent of the drug arm versus 18.7 percent, and just 1.2 percent of patients quit the pill for side effects against 11.2 percent on chemo. Rash, diarrhea, and mouth sores were common, the kind of thing patients accept when the alternative is the six-month curve.

Frank McCormick, who has chased RAS for thirty years, described the mechanism as a kind of chaperone, a helper protein that brings the drug and its target together. A gene the field had written off, drugged at last. When a release says “first in class,” it is usually reaching. Here it is accurate, and that is exactly why the rest of the story is worth telling instead of losing under the applause.

The number the survival curve doesn’t mention

Revolution set the list price at $39,800 for a 30-day supply. That is about $477,600 a year for a pill, more than double Merck’s Keytruda, the best-selling cancer drug in the world. It cleared the analysts too, who had modeled $25,000 to $30,000 a month and spent launch week revising upward. Evercore ISI now projects $2.4 billion in sales by 2027 and as much as $20.8 billion at peak, and one of its analysts called this, without irony, one of the fastest oncology launches in history, if not the fastest. The survival curve doubled. So did the questions about what the market will bear.

Then there is how it arrived so fast. Rasonque was cleared six and a half months ahead of its deadline, and not through the ordinary priority-review machinery. It came through the Commissioner’s National Priority Voucher program, a pilot FDA Commissioner Marty Makary launched in June 2025 to compress the standard ten-to-twelve-month review to one or two months for products the agency deems national priorities. The voucher was sold on three premises: lower prices, domestic manufacturing, and genuine unmet need. Pancreatic cancer answers the third without argument. A $477,600 price tag sits awkwardly on the first.

Hold the fast lane to its own standard

A faster path to a medicine that doubles survival in a disease this lethal is exactly what a leaner FDA is for, to stop making dying patients wait on bureaucratic drag. Which is why the affordability promise bolted onto that speed has to mean something.

A voucher program pitched partly on lowering prices, run by an agency whose drug-review center lost more than 1,000 employees in 2025, has to answer for what it produces. What it produced first, in oncology, is the most expensive drug in its class and a windfall Wall Street is already modeling in the tens of billions. Democratic lawmakers, Senator Bernie Sanders among them, have opened a probe asking whether a fast lane Congress never authorized becomes a lucrative favor for politically connected drugmakers. That the program came from the reform wing of this FDA does not exempt it from the question. It sharpens it. A speed advantage that flows straight into pricing power is worth watching no matter whose name is on the memo, and the affordability promise was the program’s own, not a critic’s invention.

Revolution’s answer to the price, for now, is the usual one. Some commercially insured patients, the company says, may pay as little as $0 through co-pay assistance. It is a line written for the patient reading the announcement, and it says nothing about who pays the other $477,600.

Sources

1. FDA – Approval announcement, Rasonque (daraxonrasib) for metastatic pancreatic cancer
2. CancerNetwork – RASolute 302 results: overall survival, PFS, response rate, and safety data
3. BioPharma Dive – $39,800 monthly list price, Keytruda comparison, and analyst peak-sales projections
4. Fierce Biotech – Lawmakers probe the voucher program over rushed-review and authorization concerns
5. FDA – Commissioner’s National Priority Voucher (CNPV) pilot program